Danish rejection of US price comparison
Henrik Vestergaard, acting chief executive of Lif, the Danish Pharmaceutical Industry Association, has taken aim at the USA’s most-favored-nation (MFN) drug pricing policy that would tie US prices of prescription drugs to the lowest prices paid in other developed countries.
Mr Vestergaard’s debate contribution on the matter was published last week in Dagens Pharma, a Scandinavian news and analysis outlet that focuses on the pharmaceutical and life sciences industries, and on the Lif website.
He describes a tumultuous year for the pharmaceutical industry, both globally and in Denmark, with a 100% tariff on US pharma imports agreed after months of rumors, and lingering uncertainty about how these will be implemented.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze